Viracta | Investor Relations

Month Year

Investor Alerts

May 12, 2021

Viracta Therapeutics Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates

NAVAL-1, a global pivotal trial for the treatment of relapsed/refractory EBV-positive lymphoma is on track to be initiated in Q2 2021

Viracta Therapeutics, Inc. (Nasdaq: VIRX) (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced financial results for the first quarter of...
Apr 8, 2021

Viracta Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the 20th Annual...
Mar 23, 2021

Viracta and XOMA Announce Multi-License Milestone and Royalty Monetization Transaction

Viracta to Receive $13.5 Million Upfront Cash Payment

Viracta Therapeutics, Inc. (Nasdaq: VIRX), and XOMA Corporation (NASDAQ: XOMA) announced today XOMA has purchased the potential future milestones and royalties associated with existing licenses...
- Photos 2
Mar 11, 2021

Viracta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Dr. Ivor Royston, President and Chief Executive Officer of...
Mar 4, 2021

Viracta Therapeutics Strengthens Company Leadership with New Appointments to the Board of Directors and Management Team

Stephen Rubino, Ph.D., MBA and Barry J. Simon, M.D. appointed to the Board of Directors

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has strengthened its leadership team with the appointments...
Mar 3, 2021

Viracta Therapeutics to Participate at H.C. Wainwright Global Life Sciences Conference

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Viracta will participate at the H.C. Wainwright Global Life...
Feb 24, 2021

Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement

Shares of Viracta to commence trading on the Nasdaq Global Select Market on February 25, 2021 under ticker symbol 'VIRX'

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc....
Feb 16, 2021

Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma

Resulting patent to extend Viracta's intellectual property protection into at least 2040

Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has...
Feb 11, 2021

Viracta Therapeutics to Participate in Upcoming Virtual Investor Conferences

Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the Company will participate in the upcoming LifeSci...
Dec 7, 2020

Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of its Recent End of Phase 2 Meeting with the FDA

Promising data show complete responses observed across multiple subtypes of Epstein-Barr virus positive (EBV+) lymphoma; preliminary ORR/CR of 80%/40% in T/NK-NHL and 66%/33% in DLBCL

PR Newswire, San Diego, December 7, 2020 - Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced recent...

Show per page

News Releases

Explore

Contact

Follow

Legal